-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Becker muscular dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and...
-
Product Insights
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and...
-
Product Insights
Alpha-1 Antitrypsin Deficiency (A1AD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha-1 Antitrypsin Deficiency (A1AD) pipeline market research report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha-1 Antitrypsin...
-
Product Insights
Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to the destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue and fever, and weight loss. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications, and immunosuppressants. The Rheumatoid Arthritis Drugs in Development market research report provides an overview of the Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage...
-
Sector Analysis
Duchenne Muscular Dystrophy – Opportunity Assessment and Forecast to 2030
The duchenne muscular dystrophy (DMD) market across the US and Japan was valued at $619.0 million in 2020. The market is projected to grow at a CAGR of more than 11% during the forecast period 2021-2030. The diagnosed prevalent cases of DMD are expected to increase in the US and decrease in Japan between 2020 to 2030. In 2020, the most prevalent mutation among DMD cases across both markets was deletion mutation. The least prevalent mutation type in both markets...
-
Sector Analysis
Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026
Duchenne Muscular Dystrophy (DMD) is a rare, fatal recessive X-linked genetic disorder affecting predominantly males. It occurs as a result of mutations in the dystrophin gene that leads to the deficiency of the protein dystrophin, which causes the progressive weakness and degeneration of the muscles. This report provides an assessment of the pipeline, clinical, and commercial landscape of DMD. Overall, GlobalData expects new drug approvals to drive DMD market growth over the next decade (2016–2026).
-
Product Insights
Primary Progressive Multiple Sclerosis (PPMS) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Primary Progressive Multiple Sclerosis (PPMS) Global Clinical Trials Review, H1, 2018" provides an overview of Primary Progressive Multiple Sclerosis (PPMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Progressive Multiple Sclerosis (PPMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Friedreich Ataxia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, H2, 2017" provides an overview of Friedreich Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Multiple Sclerosis: Dynamic Market Forecast to 2026
Multiple Sclerosis (MS) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the MS space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.